^




    Show legend
    Group by Gene:
    Include preclinical:

    0
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    bevacizumab
    Krabeva (bevacizumab biosimilar)
    bevacizumab-awwb
    		1
    VEGF-A inhibitor
    bevacizumab-maly
    bevacizumab-tnjn
    bevacizumab-adcd
    Byvasda (bevacizumab biosimilar)
    bevacizumab-bvzr
    temozolomide
    cisplatin
    		2
    DNA synthesis inhibitor
    dacarbazine
    gemcitabine
    mitomycin
    etoposide IV
    		3
    Topoisomerase II inhibitor
    RTA 744
    teniposide
    4
    Alkylating agent
    lomustine
    5
    Tubulin polymerization promoter
    carboplatin
    6
    MEK inhibitor, BRAF inhibitor
    trametinib + dabrafenib
    BRAF inhibitor + MEK inhibitor
    regorafenib
    anlotinib
    		7
    Multi-tyrosine kinase inhibitor
    cabozantinib tablet
    ponatinib
    pazopanib
    8
    Alkylating agent, Tubulin polymerization inhibitor
    lomustine + procarbazine hydrochloride + vincristine liposomal
    vincristine + lomustine + procarbazine hydrochloride
    9
    mTOR inhibitor
    everolimus
    VBI-1901
    AV-GBM-1
    		10
    Immunostimulant
    ERC1671
    Histone H3.3-K27M Neoantigen Vaccine Therapy
    UCPVax
    PD1 inhibitor
    		11
    PD1 inhibitor
    nivolumab
    pembrolizumab
    12
    Apoptosis stimulant
    teserpaturev
    13
    Tubulin polymerization promoter, Tubulin polymerization inhibitor
    carboplatin + vincristine
    14
    MEK1 inhibitor
    cobimetinib
    trametinib
    		15
    MEK inhibitor
    selumetinib
    PD-0325901
    EGFR inhibitor
    ERAS-801
    panitumumab
    		16
    EGFR inhibitor
    erlotinib
    gefitinib
    cetuximab
    osimertinib
    nimotuzumab
    17
    pan-RAF inhibitor
    DAY101
    dabrafenib
    		18
    BRAF inhibitor
    ABM-1310
    PLX4720
    19
    CXCL12 inhibitor
    NOX-A12
    pemigatinib
    		20
    FGFR inhibitor
    infigratinib
    ABSK091
    futibatinib
    21
    Alkylating agent, BRD4 inhibitor
    VAL-083
    22
    BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib
    FORE-8394
    GLR2007
    		23
    CDK4 inhibitor, CDK6 inhibitor
    abemaciclib
    palbociclib
    24
    Cytotoxic T lymphocyte stimulant
    DOC1021
    CAN-3110
    25
    NK cell stimulant
    CYNK-001
    26
    Oxygen radical scavenger
    OKN-007
    27
    CEBPB antagonist
    ST101
    28
    XPO1 inhibitor
    selinexor
    29
    TERT inhibitor
    RZ-001
    30
    Survivin inhibitor
    SVN53-67 / M57-KLH peptide vaccine
    31
    Immunostimulant, Cell death stimulant
    DNX-2401
    ivosidenib
    		32
    IDH1 inhibitor
    BAY1436032
    AGI-5198
    33
    ALK inhibitor
    crizotinib
    34
    ERK2 inhibitor, ERK1 inhibitor
    BVD-523
    35
    PRMT5 inhibitor
    PRT811
    TNG908
    36
    AMPK activator
    metformin
    carmustine
    		37
    Alkylating agent, DNA synthesis inhibitor
    temozolomide gel
    temozolomide + lomustine
    temozolomide + carmustine
    38
    PD-L1 inhibitor
    PD-L1 inhibitor
    atezolizumab
    39
    Reactive oxygen species stimulant, Photosensitizer
    verteporfin
    40
    VEGF-A inhibitor, Multi-tyrosine kinase inhibitor
    bevacizumab + anlotinib
    41
    EGFR inhibitor, EGFRvIII inhibitor
    WSD0922
    nivolumab + bevacizumab
    		42
    VEGF-A inhibitor, PD1 inhibitor
    bevacizumab + retifanlimab-dlwr
    pembrolizumab + bevacizumab
    43
    Microtubule inhibitor, EGFRvIII-targeted antibody-drug conjugate
    AMG 595
    44
    TNFα inhibitor
    onfekafusp alfa
    45
    VEGF-A inhibitor, EGFR inhibitor
    bevacizumab + osimertinib
    bevacizumab + erlotinib
    46
    HIF-2α inhibitor
    belzutifan
    47
    VEGFR inhibitor
    cediranib
    48
    Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
    ABT-414
    ABBV-221
    49
    DNA synthesis inhibitor, Multi-tyrosine kinase inhibitor
    anlotinib + temozolomide
    pamiparib
    		50
    PARP inhibitor
    talazoparib
    olaparib
    niraparib
    51
    DNA replication inhibitor, EGFR-targeted antibody-drug conjugate
    ABBV-321
    52
    mTOR inhibitor, BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib + everolimus
    53
    Integrin inhibitor
    cilengitide
    54
    HDAC inhibitor
    panobinostat
    romidepsin
    55
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    56
    VEGFR-2 inhibitor, DNA synthesis inhibitor
    temozolomide + rivoceranib
    57
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    58
    Chemotherapy
    PCV
    59
    BRAF inhibitor, MEK1 inhibitor, BRAF V600E inhibitor
    vemurafenib + cobimetinib
    60
    Immunotherapy
    Immunotherapy
    61
    PD-L1 inhibitor, IDH1 inhibitor
    PD-L1 inhibitor + IDH1 inhibitor
    62
    ENO1 inhibitor
    ENO1 inhibitor
    63
    Hypomethylating agent
    Hypomethylating agent
    64
    EGFRvIII-targeted CAR-T immunotherapy
    EGFRvIII-targeted CAR-T immunotherapy
    65
    Topoisomerase I inhibitor
    Topoisomerase I inhibitor
    66
    Activin receptor inhibitor
    Activin receptor inhibitor
    67
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    Bay846
    68
    Topoisomerase II inhibitor, DNA synthesis inhibitor
    cisplatin + etoposide IV
    69
    DNA synthesis inhibitor, Chemotherapy
    PCV + thioguanine
    70
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
    erdafitinib
    71
    MEK2 inhibitor, MEK1 inhibitor
    FCN-159
    72
    Vascular disrupting agent, Angiogenesis inhibitor
    VB-111
    73
    PI3K inhibitor, mTOR inhibitor, AKT inhibitor
    GDC-0084
    74
    Microtubule destabilizing agent, Vascular disrupting agent, Apoptosis stimulant
    BAL101553
    75
    ERK inhibitor, AKT inhibitor
    ONC201
    76
    DNA synthesis inhibitor, IFNα 2b stimulant
    temozolomide + interferon α-2b
    77
    Glycolysis inhibitor, Viral replication inhibitor
    WP1122
    78
    PI3K inhibitor, PKCβ inhibitor, AKT inhibitor
    enzastaurin
    79
    ERK5 inhibitor, CDK2 inhibitor, JAK2 inhibitor, CDK9 inhibitor, FLT3 inhibitor, CDK7 inhibitor, CDK1 inhibitor, CDK5 inhibitor
    TG02
    80
    IDH2 inhibitor, IDH1 inhibitor
    S95032
    81
    Gene transference, Thymidine kinase stimulant, PD1 inhibitor
    nivolumab + aglatimagene besadenovec
    82
    TSP1 stimulant, CD36 stimulant
    VT1021
    83
    BRAF inhibitor, BRAF V600E inhibitor, Cytochrome P450 inhibitor
    FORE-8394 + cobicistat
    84
    VEGFR inhibitor, PDGFR inhibitor, DNA synthesis inhibitor, c-KIT inhibitor
    sunitinib + temozolomide
    85
    Wilms tumor 1 inhibitor, Cytotoxic T lymphocyte stimulant, PD1 inhibitor, PSMA inhibitor, hTERT inhibitor, IL-12 stimulant
    cemiplimab-rwlc + INO-5401 + INO-9012
    86
    PD-L1 inhibitor, PI3K inhibitor, AKT inhibitor
    atezolizumab + RG7440
    87
    VEGFR inhibitor, HER2 inhibitor, EGFR inhibitor, EphB4 inhibitor
    KD019
    88
    RAS inhibitor, Apoptosis stimulant
    NEO100
    89
    cRAF inhibitor, MEK inhibitor, BRAF inhibitor
    binimetinib + encorafenib
    90
    ROS1 inhibitor, ALK inhibitor
    lorlatinib
    91
    CASP3 stimulant, DNA synthesis inhibitor
    temozolomide + PAC-1
    92
    TGFβ inhibitor, PD-L1 inhibitor
    M7824
    93
    JAK1 inhibitor, JAK2 inhibitor
    ruxolitinib
    94
    DNA synthesis inhibitor, PARP inhibitor
    temozolomide + ABT-888
    95
    EphA3 inhibitor, EPH receptor inhibitor
    KB004
    96
    PD-L1 inhibitor, MEK1 inhibitor
    atezolizumab + cobimetinib
    97
    VEGF-A inhibitor, ERK inhibitor, AKT inhibitor
    bevacizumab + ONC201
    98
    DNA synthesis inhibitor, EGFR inhibitor, Multi-tyrosine kinase inhibitor
    anlotinib + temozolomide + aumolertinib
    99
    Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor
    ABT 263
    100
    DNA synthesis inhibitor, DNA methylation inhibitor
    temozolomide + azacitidine
    101
    FGFR3-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    AMB302
    102
    EGFR MasterKey inhibitor, EGFR inhibitor
    BDTX-1535
    103
    α radiation emission, EGFRvIII inhibitor
    Undisclosed EGFRvIII-targeted alpha therapy
    104
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, MEK inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    trametinib + entrectinib
    105
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, CDK4 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, CDK6 inhibitor, TNK2 inhibitor
    entrectinib + abemaciclib
    106
    Telomerase inhibitor, VEGF-C inhibitor, NF-κB inhibitor
    sodium metaarsenite
    107
    IGF-1R inhibitor
    ASP7487
    108
    IL-7 agonist
    efineptakin alfa
    109
    Tubulin polymerization promoter, Tubulin polymerization inhibitor, DNA synthesis inhibitor
    carboplatin + temozolomide + vincristine
    110
    Topoisomerase II inhibitor, DNA intercalator
    daunorubicin
    111
    BMI1 inhibitor
    PTC-209
    112
    Tubulin polymerization inhibitor
    vincristine
    113
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    114
    DNMT inhibitor
    decitabine
    115
    ATR inhibitor, PARP inhibitor
    olaparib + AZD6738
    116
    NEDD8 activating enzyme inhibitor
    MLN4924
    117
    PKC inhibitor
    RO-31-8220
    118
    Nicotinamide phosphoribosyltransferase inhibitor
    APO866
    119
    CDK4 inhibitor, BRAF inhibitor, CDK6 inhibitor
    palbociclib + PLX4720
    120
    VEGFR-2 inhibitor
    rivoceranib
    121
    WEE1 inhibitor
    AZD1775
    122
    PD-L1 inhibitor, DNA synthesis inhibitor
    atezolizumab + temozolomide
    123
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    124
    MDM2-p53 antagonist
    BI 907828
    125
    PTP-1B inhibitor
    claramine
    126
    CD133-targeted CAR-T immunotherapy
    CD133-specific CAR-T cell therapy
    127
    PARP1 inhibitor, DNA synthesis inhibitor
    temozolomide + AZD9574
    128
    CDK2 inhibitor, CDK9 inhibitor, CDK7 inhibitor
    CYC065 + SY‑079
    129
    mTOR inhibitor, Multi-tyrosine kinase inhibitor
    everolimus + vandetanib
    130
    Proteasome inhibitor
    NPI-0052
    131
    MCL1 inhibitor, Protein synthesis inhibitor, MYC inhibitor, Apoptosis stimulant, G1-S-specific cyclin-D1 inhibitor
    omacetaxine mepesuccinate
    132
    Topoisomerase II inhibitor, RNA synthesis inhibitor
    dactinomycin
    133
    Androgen receptor inhibitor, AKT inhibitor
    enzalutamide capsule + MK-2206
    134
    HER2 inhibitor, HER4 inhibitor, Androgen receptor inhibitor, EGFR inhibitor
    afatinib + enzalutamide capsule
    135
    ATM kinase inhibitor
    AZD1390
    No biomarker
    BRAF V600E
    BRAF mutation
    BRAF V600
    BRAF T599
    BRAF fusion
    BRAF wild-type
    IDH1 mutation + Chr del(1p) + Chr del(19q)
    IDH1 mutation
    IDH1 R132H
    IDH1 overexpression
    IDH2 mutation
    IDH2 mutation + Chr del(1p) + Chr del(19q)
    MGMT unmethylation
    IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E
    IDH1 mutation + BRAF V600E
    MGMT promoter methylation
    IDH1 wild-type + BRAF mutation
    MGMT underexpression
    IDH1 mutation + NTRK3 fusion
    IDH2 mutation + NTRK1 fusion
    IDH2 mutation + NTRK2 fusion
    IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion
    IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion
    IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion
    IDH2 mutation + NTRK3 fusion
    IDH1 mutation + NTRK1 fusion
    IDH1 mutation + NTRK2 fusion
    IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion
    IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion
    IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion
    IDH2 mutation + BRAF V600E
    IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E
    EGFR mutation
    EGFRvIII mutation
    EGFR amplification
    EGFR exon 2-7 deletion + EGFR amplification
    EGFR L858R
    EGFR overexpression
    EGFR expression
    EGFRVIII overexpression
    EGFR A289V
    EGFRvIII expression
    EGFR exon 20 insertion + EGFR T790M
    NF1 mutation
    NF1 deletion
    NF1 2195G>T
    NF1 470G>T
    IDH wild-type
    FGFR3-TACC3 fusion
    MET amplification
    TP53 mutation
    TP53 wild-type
    MET fusion
    MET overexpression
    NTRK3 fusion
    PD-L1 overexpression
    TMB-H
    FGFR mutation
    TMB-L
    FGFR fusion
    PIK3CA mutation + TTN mutation + IDH2 mutation + Chr del(1q) + Chr del(17)
    NRAS mutation
    PIK3CA mutation + TTN mutation + IDH2 mutation
    NRAS wild-type
    PD-L1 expression
    EGFRVIII expression + PTEN expression
    ETV6-NTRK3 fusion
    BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion
    BRAF V600E + TERT mutation
    BRAF V600E + PIK3CA mutation
    TP53 mutation + TSC2 mutation
    ALK fusion
    FGFR1-TACC1 fusion
    ZCCHC8-ROS1 fusion
    IDH wild-type + FGFR3 S249C + TP53 V73fs
    BRAF V600E + SOX2 amplification
    SP140 overexpression
    PDX1 mutation
    EP400 mutation
    DOCK8 mutation
    IDH2 mutation + TMB-L
    IDH1 mutation + TMB-L
    FGFR1 mutation
    HLA-A*02 + H3K27M
    CDK4 amplification
    CXCL12 expression
    BCL7A overexpression
    IDH1 mutation + WT1 overexpression
    NEAT1 overexpression
    ABCB1 G412G
    EPHA3 positive
    NID1 expression
    FERMT3 overexpression
    PLEKHA4 underexpression
    KIAA1549-BRAF fusion
    KRAS wild-type
    PDGFRA amplification + KDR amplification
    IDH1 wild-type + NF1 mutation
    NACC2-NTRK2 fusion
    IDH2 mutation + MYC amplification + MAPRE1 overexpression
    IDH1 mutation + MYC amplification + MAPRE1 overexpression
    TERT C228T + FGFR3 amplification + FGFR3-TACC3 fusion
    GOPC-ROS1 fusion
    VEGFA-L
    MMP9-L
    NTRK1 fusion
    NTRK2 fusion
    MSI-H/dMMR
    PTEN mutation
    P4HB underexpression
    PDIA3 underexpression
    AGT underexpression
    HLA-DQA1 overexpression
    IDH1 mutation + MGMT promoter methylation
    IDH2 mutation + MGMT promoter methylation
    PIK3CA mutation + IDH2 mutation + Chr del(1q) + Chr del(17)
    CDKN2A-DT deletion
    TTN mutation + IDH2 mutation
    CDH2 underexpression
    CD36 overexpression
    TERT 124C>T
    CD47 overexpression
    miR-30b-3p underexpression
    MMP2 elevation
    PRSS3 underexpression
    VHL mutation
    FGFR2 fusion
    PTEN deletion
    VEGFA overexpression
    VEGFA elevation
    CDK4 overexpression
    H3.3K27M
    Chr del(1p)
    Chr del(1p)+ Chr del(19q)
    GSTP1 313A>G
    MTAP deletion
    STAG2 mutation
    MDM2 amplification
    PPM1B overexpression
    MET overexpression + KDR overexpression
    GSTP1 overexpression
    BCL3 overexpression
    KDR overexpression
    REST signature
    PTPN1 overexpression
    CD133 positive
    ASAP1 overexpression
    KLC1-ROS1 fusion
    GJA1 overexpression
    NTRK-ROS1 fusion
    PLK2 underexpression
    CXCL8 overexpression
    SAA1 underexpression
    ACVR1 R206H
    CD44 positive
    ATRX mutation
    BIRC5 mutation
    ATRX deletion
    CENPI overexpression
    JARID2 overexpression
    MIF overexpression
    ACVR1 mutation
    MSH2 deletion
    PIGF overexpression
    RB1 expression
    TERT mutation + EGFR T790M + EGFR exon 20 insertion
    AIM2 deletion
    ROS1 fusion
    FLT1 overexpression
    TERT mutation + MGMT promoter methylation
    PIGF elevation
    FLT1 elevation
    CCND1 overexpression
    AKT1 overexpression
    EPAS1 overexpression
    miR-370 underexpression
    RUNX1 overexpression
    VPS18 overexpression
    CD8 positive
    CTSS overexpression
    FCER1G expression
    GSTM1 expression + GSTM5 expression
    NGFR expression
    BMI1 overexpression
    CD133 expression
    PGP expression
    LIFR expression
    NCAM1 expression
    PDGFRA amplification + NTRK2 fusion
    SETD2 mutation + MGMT promoter methylation
    IDH1 R132S + H3K27me3 loss + MET exon 14 skipping mutation
    ENO1 deletion
    CDKN2A deletion
    BICD1 overexpression
    IDH1 mutation + ATRX deletion + TP53 deletion
    DKK3 overexpression
    FABP7 overexpression
    TNFA overexpression
    FGFR3 overexpression
    AEBP1 overexpression